The aim of the present study was to evaluate the safety , tolerability , clinical and haemodynamic impact of add-on sildenafil in patients with congenital heart disease ( CHD ) - related pulmonary arterial hypertension ( PAH ) and Eisenmenger physiology after failure of oral bosentan therapy .
